CFLAR and ovarian carcinoma: So far, except for siRNAs approaches, c-FLIP inhibitors that have been studied act indirectly on c-FLIP, such as Cisplatin, which induces p53-dependent FLIP ubiquitination and degradation in ovarian cancer cells [27], or Actinomycin D, which downregulates FLIP(L) and FLIP(s) expression in B chronic lymphocytic leukemia [28].